News & Updates
Filter by Specialty:
Benralizumab helps maintain severe asthma control with reduced ICS doses
Treatment with benralizumab allows tapering of inhaled corticosteroid (ICS) doses for patients with severe eosinophilic asthma, without compromising disease control and increasing exacerbations, as shown in the results of the phase IV SHAMAL study.
Benralizumab helps maintain severe asthma control with reduced ICS doses
22 Sep 2023
Cefoperazone-sulbactam superior to piperacillin-tazobactam for severe CAP
Treatment with cefoperazone-sulbactam demonstrates similar efficacy to that of piperacillin-tazobactam in adult patients with severe community-acquired pneumonia (SCAP), according to a study. However, after adjusting for disease severity, cefoperazone-sulbactam appears superior to piperacillin-tazobactam.
Cefoperazone-sulbactam superior to piperacillin-tazobactam for severe CAP
21 Sep 2023
Budesonide falls short of improving hyposmia related to COVID-19
Local intranasal treatment with budesonide does not appear to be effective for persistent hyposmia in patients with nonsevere COVID-19, according to a study.
Budesonide falls short of improving hyposmia related to COVID-19
21 Sep 2023
Sleep problems tied to risk of COVID-19 outcomes
A cross-sectional analysis has found an association between insomnia, poor sleep quality, and extremes of sleep duration and increased COVID-19 infection and hospitalization.
Sleep problems tied to risk of COVID-19 outcomes
18 Sep 2023
Durvalumab plus radiotherapy shows promise in unresectable NSCLC
In the treatment of patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, and locally advanced nonsmall cell lung cancer (NSCLC), the use of durvalumab immunotherapy in combination with curative radiotherapy yields survival gains with tolerable adverse events (AEs), as shown in the results of the phase II DOLPHIN trial.